$SIHUAN PHARM.HK$HUTCHMED.HK中信建投研报指出，ASCO 是广受关注的全球临床肿瘤学大会，其数据发布具有较高的行业影响力。2023 年 ASCO 大会将在美东时间 6 月 2 日-6 月 5 日举行，一批海外及中国企业将于大会上发布重要临床数据。本次 ASCO 大会从口头报告构成看，单抗和小分子依然为主流，ADC 则继续崛起，成为第三大品类。我们看好创新药产业技术驱动周期，建议关注 ADC 及新型疗法。
Likes Received
Platinum TraderThe copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Like